Biomaterial-enabled in vivo T cell engineering: A new paradigm for cell therapy
Cell Biomaterials · 2026-08 · 100558
DOI: 10.1016/j.celbio.2026.100558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biomaterials, 2026-08. Verfasst von Sharda Pandit und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Chapel Hill, N…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
T cell therapies have transformed treatment for previously intractable diseases. However, their full potential remains constrained by reliance on ex vivo cell manipulations, which reduces cell quality, drives up manufacturing costs, and requires lengthy production times, ultimately reducing treatment efficacy and restricting patient access. Recent breakthroughs in biomaterials science, immunoengineering, and genetic editing have catalyzed a paradigm shift toward direct in vivo immune cell engineering using instructive biomaterials. These emerging strategies circumvent traditional limitations by dramatically reducing costs, eliminating manufacturing delays, and improving therapeutic outcomes through preservation of native cell states and functions. Key technological advances include highly specific targeted biomaterial-assisted gene delivery and instructive biomaterials that establish controlled microenvironments for precise immune cell programming and modulation. In this Perspective, we examine how biomaterials are redefining T cell therapies across a range of pathological contexts, from cancer to autoimmune disease. We analyze emerging breakthrough platforms, highlight their therapeutic potential, and discuss key challenges limiting clinical adoption. Looking ahead, we provide insights into future developments that could democratize access to these transformative immunotherapies.
Autor:innen und Institutionen
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Chapel Hill, NC, USA.
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, USA.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Institutes of Health National Cancer Institute
Zitieren
APA
Pandit, S., Oliver, S. A., Joe, E., & Brudno, Y. (2026). Biomaterial-enabled in vivo T cell engineering: A new paradigm for cell therapy. Cell Biomaterials, 100558. https://doi.org/10.1016/j.celbio.2026.100558
Vancouver
Pandit S, Oliver SA, Joe E, Brudno Y. Biomaterial-enabled in vivo T cell engineering: A new paradigm for cell therapy. Cell Biomaterials. 2026:100558. doi:10.1016/j.celbio.2026.100558
BibTeX
@article{Pandit2026,
author = {Pandit, Sharda and Oliver, S Abbey and Joe, Emily and Brudno, Yevgeny},
title = {Biomaterial-enabled in vivo T cell engineering: A new paradigm for cell therapy},
journal = {Cell Biomaterials},
year = {2026},
pages = {100558},
doi = {10.1016/j.celbio.2026.100558}
}
EUVIMED